Relief on fibrosis past acute rejection of the rat allograft artery from the specific 5-HT2A receptor blocker,sarpogrelate
10.3760/cma.j.issn.0254-1785.2011.09.014
- VernacularTitle:选择性5-HT2A受体拮抗剂沙格雷酯延缓大鼠移植动脉急性排斥反应后纤维化
- Author:
Haihao WANG
;
Ming LI
;
Min WU
;
Weijie ZHANG
;
Zhishui CHEN
;
Jun YANG
- Publication Type:Journal Article
- Keywords:
Rats;
Arteries;
Transplants;
Fibrosis;
Sarpogrelate
- From:
Chinese Journal of Organ Transplantation
2011;32(9):562-565
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of sarpogrelate, a specific 5-HT2A receptor blocker,on fibrosis past acute rejection of abdominal aortic allotransplantation in rats. MethodsThe rat models of abdominal aortic transplantation were divided into three groups: allograft control group (Wistar→ SD), isograft control group ( SD→ SD) and sarpogrelate-treated group (Wistar→ SD).Sarpogrelate-treated group receivedintragastric administration of sarpogrelate every day. The pathologic and immunohistochemical findings of the transplant aorta were observed at 14th and 60th day after transplantation. ResultsAt 14th day, visible acute rejection could be observed in allograft control group,but not in isograft control group. At 60th day, vascular intimal index of sarpogrelatetreated group was significantly lower than that in allograft control group[( 16. 71 ± 3. 94)％ versus (62. 41 ± 6. 54)％ ,P＜0. 05). The expression of PCNA and α-SMA in sarpogrelate-treated group wasalso significantly lower than that in allograft control group[(7. 37 ± 4. 61)％ versus (22. 43 ±3.40)％,(8.21 ± 3. 11)％ versus. (23.70 ± 2.78)％, P＜0.05, respectively). Conclusion The expression of PCNA and α-SMA of the transplant aorta could be suppressed by sarpogrelate, and sarpogrelate could relieve the fibrosis past acute rejection of aortic allograft.
